---
title: 'Overall survival of cHL patients who progress after autologous stem cell transplant:
  results in novel agent era'
date: '2023-09-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37729621/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230921190649&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: In pre-novel agent era, median post progression overall survival (PPS)
  of classic Hodgkin lymphoma (cHL) patients (pts) who progress after ASCT have been
  2-3 years. Recently, Checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have
  improved depth and durability of response in this population. Here we report estimate
  of PPS in pts with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter
  retrospective study of 15 participating institutions, adult pts with relapsed cHL
  ...
disable_comments: true
---
In pre-novel agent era, median post progression overall survival (PPS) of classic Hodgkin lymphoma (cHL) patients (pts) who progress after ASCT have been 2-3 years. Recently, Checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved depth and durability of response in this population. Here we report estimate of PPS in pts with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult pts with relapsed cHL ...